All In MedTech

FDA Clearance Tracker · P160050

BARRICAID ANULAR CLOSURE DEVICE (ACD)

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Feb 8, 2019 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product code

The decision

FDA number
P160050
Device name
BARRICAID ANULAR CLOSURE DEVICE (ACD)
Applicant location
Woburn, MA
Received
Nov 10, 2016
Decided
Feb 8, 2019
Decision
Approved
Supplements
11 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code QES

FDA's approval statement

As written in FDA's record.

Approval for the Barricaid Anular Closure Device (ACD). The device is indicated for reducing the incidence of reherniation, and reoperation in skeletally mature patients with radiculopathy (with or without back pain) attributed to a posterior or posterolateral herniation, and confirmed by history, physical examination and imaging studies which demonstrate neural compression using MRI to treat a large anular defect (between 4-6 mm tall and between 6-10 mm wide) following a primary discectomy procedure (excision of herniated intervertebral disc) at a single level between L4 and S1.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code QES (Reherniation reduction device).
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Intrinsic Therapeutics

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.